Moderna reported a surprise profit in Q3, exceeding expectations with a net income of $13 million driven by higher Covid vaccine sales. The biotech company aims to cut costs and expand its product portfolio, focusing on mRNA technology. Despite challenges, Moderna remains optimistic about its future growth.